Wandercraft Announces CE Mark Expansion for Atalante X, Advancing Care for Patients with Tetraplegia and Other Complex Neurological Conditions
.jpg)
Paris, France (August 19th, 2025) — Wandercraft, the global leader in self-balancing robotic exoskeletons, announced that its next-generation flagship device, Atalante X, has received expanded CE Mark certification. Building on real-world use at more than 100 rehabilitation centers, the new Atalante X introduces improved control, enhanced clinical features, and expanded indications to address a wider range of neurologic conditions regardless of the underlying cause, including:
- Paraplegia and paraparesis
- Tetraplegia and tetraparesis
- Hemiplegia and hemiparesis
This expansion is supported by retrospective safety data and prospective studies, including a clinical trial with patients who have multiple sclerosis (MS) and cases involving high-level spinal cord injuries and Guillain-Barré syndrome. Since its original launch, Atalante X has been used by more than 100 patients with tetraplegia or tetraparesis – accounting for 12% of total users – demonstrating its unique ability to treat complex cases.
Smarter Adaptation for Targeted Therapy
The latest version features joint-specific assistance control, enabling clinicians to independently adjust the exoskeleton’s assistance at the hip and knee motors on each leg. This targeted approach gives therapists new tools to tailor treatment to the unique motor profile of each patient, from early-stage recovery to long-term strengthening.
“These advances will unlock important new opportunities in neurorehabilitation,” said Maria Iacono, Chief of RAQA & Clinical Global at Wandercraft. “Therapists will be able to align device settings not only with clinical protocols but also with each patient’s functional goals and evolving needs.”
Refined Gait Customization for Progressive Recovery
With more precise step-length adjustments in 5% increments, therapists can now facilitate smoother, more personalized progression during walking sessions. This flexibility is especially useful for individuals with spasticity, limited hip extension, or in early stages of ambulation. Clinicians can now more precisely align therapy with patients’ comfort, confidence, and physical ability – promoting a more natural return to upright mobility.
“The ability to independently control support at each joint gives us a new level of precision. We can now customize therapy in ways that were simply not possible before,” said Margaux Blum, PT, Head of Customer Care at Wandercraft. “Patients gain confidence when the system adapts to them – rather than forcing them to adapt to the system. That’s what Atalante X enables.”
Enhanced Safety, Usability, and Data Insights
The update to the Atalante X system also includes:
- Enhanced graphical data in patient reports now display assistance values below zero, providing clinicians with a more complete view for improved clinical tracking.
- Updated training protocols for clinician onboarding.
- Enhanced safety procedures embedded into digital workflows.
- Refined hardware components, including more durable foam support.
Seamless Deployment and Market Timeline
The new Atalante X will start shipping to European customers in October 2025, with existing Wandercraft clinical partners receiving the upgrade automatically as part of the company’s long-term support and continuous innovation model. The U.S. regulatory submission for FDA clearance is underway, aiming to extend the indication to individuals with spinal cord injuries from levels C4 to L5 (SCI) as well as to those with multiple sclerosis (MS). Clearance is expected by the end of this year.
About Wandercraft
Wandercraft is a global robotics company on a mission to restore mobility and expand what’s possible through self-balancing, AI-powered systems. Known for its groundbreaking Personal Exoskeleton, Eve, Wandercraft is developing the next generation of mobility solutions to restore walking ability both at home and in rehabilitation. Its flagship device, the Atalante X, is a groundbreaking self-balancing exoskeleton used at more than 100 inpatient and outpatient rehabilitation centers.
In 2025, Wandercraft expanded into industrial robotics with the launch of Calvin-40, a strong, voice-controlled humanoid robot developed through a strategic partnership with Renault Group. Built on the same life-tested robotics platform as Wandercraft’s medical exoskeletons, Calvin is engineered to perform physically demanding or hazardous tasks in real-world environments, starting with automotive manufacturing. With more than 30 patents and a deeply human mission, Wandercraft believes that everyone should have the chance to move freely – and that robotics should connect with people where they are, with reliability, responsiveness, and purpose. Learn more at wandercraft.eu.
Media Contact
Lilly Kofler
Global Head of Marketing & Communications